Outcomes of cytoreductive surgery for octogenarian patients with high-grade serous ovarian cancer: A Single-center experience

BACKGROUNDTreatment of high-grade serous ovarian cancer (HGSOC) is composed of combination of cytoreductive surgery and systemic therapy.There is scarce literature pertaining to the morbidity and feasibility of this treatment in elderly patients. AIMTo describe treatment patterns, postoperative morbidity, and survival outcomes among octogenarian patients with HGSOC managed by surgery at a tertiary referral center.≥ III, 4.8%), 30-and 90-day mortality were each 2.4%, and the median length of stay was 5 days.The median PFS was 25 months, and the median OS was 37 months.Patients treated with PCS experienced significantly longer OS compared with those treated with NACT (median months 43 vs 24 months; OS: P = 0.01).On multivariable Cox regression analysis, receipt of PCS (hazard ratio 0.29; 95% confidence interval: 0.10-0.80)was independently associated with improved OS, while worse Eastern Cooperative Oncology Group performance status was independently associated with worse OS. CONCLUSIONIn a surgically selected population, carefully selected women aged 80 years or older with HGSOC can achieve meaningful survival outcomes, particularly when suitable candidates for PCS.Treatment decisions should be guided by functional status and comorbidity burden rather than chronological age alone.